Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
Ocugen获批加入治疗Stargardt病药物候选剂高剂量研究
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册